Xuetao Shi

Featured in: Favicon

nature.com Favicon

frontiersin.org Favicon

biomedcentral.com Favicon

onlinelibrary.wiley.com Favicon

bmccancer.biomedcentral.com + 2 more

Articles

Reconstructing the Stem Leydig Cell Niche via the Testicular Extracellular Matrix for the Treatment of Testicular Leydig Cell Dysfunction

Nov 18, 2024 | onlinelibrary.wiley.com | Jie Liu |Zhichen Zhai |Engineering South |Xuetao Shi

1 Introduction As testicular multipotent stromal cells, stem Leydig cells (SLCs) act as a reserve progenitor population that is essential for testis development, homeostasis, and regeneration.
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial | Nature Communications

Apr 15, 2024 | nature.com | Zhongchao Li |Bo Zhang |Xuetao Shi |Kai Cui |Zhicheng Sun |Mingming Li | +3 more

AbstractNotable-HCC (NCT05185531) is a phase 1b trial, aiming to evaluate the safety and preliminary effectiveness of neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT) in early-stage resectable hepatocellular carcinoma (HCC). Twenty patients with HCC of BCLC stage 0-A received 3\(\times \) Gy SBRT and two cycles of tislelizumab, an anti-PD-1 monoclonal antibody before the curative HCC resection.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →